Irini Veronikis, MD
Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1578508701
Payments from drug & device makers
Across 277 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$628
- Abbott$605
- Novo Nordisk$487
- Lilly USA, LLC$353
- Sequel Med Tech, LLC$258
- Amgen$245
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,83899%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 43 | $628 |
| Abbott | 49 | $605 |
| Novo Nordisk | 27 | $487 |
| Lilly USA, LLC | 16 | $353 |
| Sequel Med Tech, LLC | 17 | $258 |
| Amgen(2 entities) | 14 | $245 |
| Xeris Pharmaceuticals, Inc. | 11 | $229 |
| Novartis | 10 | $191 |
| Medtronic(2 entities) | 7 | $160 |
| Radius Health, Inc. | 5 | $117 |
| Sanofi-aventis U.S. LLC | 5 | $112 |
| Acella Pharmaceuticals, LLC | 3 | $110 |
| Recordati_rare_diseases_inc. | 4 | $105 |
| AstraZeneca | 5 | $101 |
| Mannkind Corporation | 5 | $99 |
| Boehringer Ingelheim | 5 | $93 |
| Almatica Pharma LLC | 5 | $90 |
| Bayer | 4 | $87 |
| Amneal Pharmaceuticals LLC | 4 | $85 |
| Corcept Therapeutics | 3 | $70 |
| Madrigal Pharmaceuticals | 2 | $70 |
| AbbVie | 3 | $63 |
| Averitas Pharma Inc. | 3 | $61 |
| Tandem Diabetes Care, Inc. | 4 | $58 |
| BETA Bionics, Inc. | 6 | $57 |
| Amphastar Pharmaceuticals, Inc. | 3 | $54 |
| Verity Pharmaceuticals Inc. | 2 | $53 |
| IBSA Pharma Inc. | 3 | $51 |
| Nevro Corp. | 1 | $31 |
| Chiesi USA, Inc. | 1 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Insulet Corporation | 1 | $11 |
How this compares
$4,877 in reported general payments places this provider in the 60th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 182 | $268,531 |
| JardianceEmpagliflozin | 222 | $266,884 |
| TrulicityDulaglutide | 93 | $152,613 |
| MounjaroTirzepatide | 79 | $103,270 |
| Teriparatide | 30 | $79,042 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $59,562 |
| Tresiba Flextouch U-100Insulin Degludec | 63 | $51,017 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $40,484 |
| FarxigaDapagliflozin Propanediol | 29 | $36,842 |
| TymlosAbaloparatide | 15 | $36,566 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $32,068 |
| JanuviaSitagliptin Phosphate | 16 | $25,116 |
| SynthroidLevothyroxine Sodium | 259 | $23,474 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 110 | $22,002 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $17,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $93 | $275,814238 claims |
| Novo NordiskOzempic, Novolog | $487 | $275,257206 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $353 | $269,704231 claims |
| AstraZenecaFarxiga | $101 | $36,84229 claims |
| Radius Health, Inc.Tymlos | $117 | $36,56615 claims |
| AbbVieSynthroid | $63 | $23,474259 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $85 | $11,2011,164 claims |
| Sanofi-aventis U.S. LLCLantus | $112 | $1,53921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Louis
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Julie SilversteinSaint Louis$536K
- Sandeep DhindsaSaint Louis$173K
- Maamoun SalamSaint Louis$170K
- Michael WhyteSaint Louis$133K
- Fumihiko UranoSaint Louis$122K
- Farid RomanSaint Louis$62K
- Kathryn DiemerSaint Louis$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.